BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15070668)

  • 1. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
    Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
    Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
    Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
    J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
    Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
    Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
    N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.
    Matucci A; Liotta F; Vivarelli E; Dies L; Annunziato F; Piccinni MP; Nencini F; Pratesi S; Maggi E; Vultaggio A
    Front Immunol; 2018; 9():1198. PubMed ID: 29896203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
    Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
    J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benralizumab for
    Kuang FL; Legrand F; Makiya M; Ware J; Wetzler L; Brown T; Magee T; Piligian B; Yoon P; Ellis JH; Sun X; Panch SR; Powers A; Alao H; Kumar S; Quezado M; Yan L; Lee N; Kolbeck R; Newbold P; Goldman M; Fay MP; Khoury P; Maric I; Klion AD
    N Engl J Med; 2019 Apr; 380(14):1336-1346. PubMed ID: 30943337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-interleukin-5 therapy for eosinophilic diseases].
    Simon D; Braathen LR; Simon HU
    Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New insights into hypereosinophilic syndromes].
    Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
    Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW; Ring J; Huss-Marp J; Kahn JE
    J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
    Stokes K; Yoon P; Makiya M; Gebreegziabher M; Holland-Thomas N; Ware J; Wetzler L; Khoury P; Klion AD
    Clin Exp Allergy; 2019 Dec; 49(12):1598-1604. PubMed ID: 31657082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
    Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
    N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
    [No Abstract]   [Full Text] [Related]  

  • 16. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
    J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IL-5 and hypereosinophilic syndromes.
    Sutton SA; Assa'ad AH; Rothenberg ME
    Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
    Roufosse F; Kahn JE; Rothenberg ME; Wardlaw AJ; Klion AD; Kirby SY; Gilson MJ; Bentley JH; Bradford ES; Yancey SW; Steinfeld J; Gleich GJ;
    J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Verstovsek S; Tefferi A; Kantarjian H; Manshouri T; Luthra R; Pardanani A; Quintás-Cardama A; Ravandi F; Ault P; Bueso-Ramos C; Cortes JE
    Clin Cancer Res; 2009 Jan; 15(1):368-73. PubMed ID: 19118067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.